|
|||
   |
|||
News & Updates
New Studies Now Open
Study Updates
Links
New Studies Now Open
RTOG 0617: A Randomized Phase III Comparison of Standard-dose (60 Gy) versus High-dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/ Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.
GOG 0218: A Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab Followed by Placebo versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal Cancer.
Study Updates
Initial Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer.
In STAR, both drugs reduced the risk of developing invasive breast cancer by about 50 percent. In addition, within the study, women who were prospectively and randomly assigned to take raloxifene daily, and who were followed for an average of about four years, had 36 percent fewer uterine cancers and 29 percent fewer blood clots than the women who were assigned to take tamoxifen.For you convenience, links to related information regarding Clinical Trials and Research:
Clinical Trial Links
www.centerwatch.com
www.clinicaltrials.gov
www.cancertrials.com
www.breastcancertrials.org
Research Links
National Cancer Institute
National Institutes of Health
Health and Human Services
Food & Drug Administration
[back to top]